Introduction
Chronic lymphocytic leukemia (CLL) is a cancer characterized by the uncontrolled proliferation and accumulation of B-cell lymphocytes 18 . It is the most commonly diagnosed leukemia in the Western world 32 . In 2017, it is estimated that over 20,000 cases will be diagnosed in the United
States, comprising of approximately a third of newly diagnosed leukemias 33 . Age-adjusted incidence rates are especially high for the 65 and older population, at 20.6 per 100,000 34 . Such elderly patients are also particularly prone to adverse outcomes driven by comorbidity 35 . While CLL prognosis varies, its beginning is often asymptomatic and insidious 30, 32 . Therefore, CLL detection is contingent on regular checkups and blood tests, and as such, its epidemiological prevalence is likely to be underestimated. While the onset of CLL is gradual, as its name suggests, it nevertheless poses economic strain on both the healthcare system and individual patients while lowering their qualities of life 31 . For these reasons, CLL is an important public health consideration with significant social and economic costs.
While CLL remains non-curative, progress has been made to better manage the disease. Earliest breakthroughs in treatment include the use of alkylating agents such as chlorambucil, which continues to be used in combination with other therapies 37 . Alkylating agents remained the standard of care between the 1950s and 1980s, after which fludarabine, a purine nucleoside analogue, was introduced in CLL therapy 36 . Notable studies determined fludarabine's advantage over chlorambucil with respect to response rates and remission duration, and it soon became a mainstay of CLL treatment 38, 39 . Immunochemotherapy entered serious therapeutic consideration for CLL when rituximab was introduced at the turn of the century. Rituximab targeted CD20 on the surface of B-cells and was incorporated into landmark combination therapies with fludarabine and cyclophosphamide 36 13 .
Despite progress in understanding the role of BAFF/APRIL signaling in healthy and neoplastic B-cells, the role of BAFF-mediated NFκB activation in CLL remains understudied.
An important mechanism through which the BAFF and APRIL survival factors work is in the activation of Bcl-2 family proteins 13 . This system contains pro-apoptotic and anti-apoptotic proteins that are maintained in a balanced fashion. B-cells transducing survival signals from extrinsic factors in their microenvironments encourage the activity of anti-apoptotic proteins of the Bcl-2 family, pushing the balance toward survival 23 . If the pro-apoptotic proteins Bak and
Bax are uninhibited to a threshold degree, they oligomerize and permeabilize the mitochondrial membrane 23 . This initiates the release of caspase-activating factors such as cytochrome c into the cytoplasm, which results in the cleavage of cellular proteins and leads to cell death. This response, however, is inhibited by the anti-apoptotic proteins, which indicates that the Bcl-2 family proteins can be harnessed to promote both cell survival and cell death.
There are a number of pathways that mediate survival factors expressed by stromal cells and apoptosis avoidance through the Bcl-2 protein family. CLL cells in the microenvironments of the lymph node, for example, display gene signatures that indicate the activation of the BCR and nuclear factor-κB (NFκB) pathways 5 . The therapeutic inhibition of BCR-associated kinases has significantly impacted CLL outcomes, in part, by causing B-cell migration from niches that provided stromal support 6 . However, patients who progress on, or are intolerant of BCRi therapy, have poor outcomes 7, 8 . Improved understanding of microenvironment signaling through other pathways will foster development of novel therapeutic approaches in CLL. This work focuses on one such pathway, the NFκB signaling pathway. Like other TNFR ligands, BAFF/APRIL activate NFκB signaling. This is a major common pathway which mediates antiapoptotic responses in CLL cells through induction of Bcl-2 family proteins and chemokine networks 13, 14, 15, 16, 17 . Both signal through BCMA/TACI to activate the canonical NFκB in CLL, where the IκB kinase complex phosphorylates IκB , triggering its ubiquitination and leading to nuclear translocation of the NFκB dimers, predominantly p50/RelA and p50/c-Rel 9, 14 . This, in turn, leads to a survival response.
BAFF also works through non-canonical NFκB signaling and can be initiated via the BAFF receptor, also known as BR3. Its activation mechanism via the BAFF/BR3 interaction will be delineated as follows. When BR3 is stimulated by the BAFF ligand, it frees the NF-κB inducing kinase (NIK) to phosphorylate the IκB kinase (IKKα). NIK also directly phosphorylates p100 at two sites: Ser-866 and Ser-870. IKKα activation via NIK phosphorylates p100 at the Ser-822 site 24 . Once all three serine sites are phosphorylated, p100 is processed into p52, dimerizes with RelB, enters the nucleus, and initiates the transcription of pro-survival BCL-2 family proteins 24 .
Of note, there is a particular mechanism by which NIK is activated to initiate phosphorylation of IKKα and p100. The non-canonical BAFF signaling pathway is constantly repressed 25 . When no ligand is attached to the BAFF receptor, NIK is constitutively targeted for ubiquitination and then degraded 25 . Cellular inducer of apoptosis proteins (cIAPs) 1 and 2 are responsible for the ubiquitination of NIK 26 . However, cIAP does not perform its function autonomously. It first binds to tumor necrosis factor receptor-associated factor 2 (TRAF2), leading to dimerization with TRAF3, which is bound to NIK. The association of TRAF3 and NIK is known to be essential to NIK degradation 25 . The TRAF2 and TRAF3 complex allows cIAP to ubiquitinate NIK 26 . This constant process prevents NIK from being active.
Activation of NIK requires that TRAF 3 must be inhibited 26 . During BAFF receptor activation, the receptor recruits TRAF 3, TRAF 2, and cIAP to its receptor domain 27 . At this point, cIAP
ubiquitinates TRAF 3 and target it for degradation 26 . Consequentially, without TRAF 3, NIK accumulates until it is energetically favored to phosphorylate IKKα and p100 27 . Preliminary experiments have suggested that BAFF stimulation has also upregulated the phosphorylation of a protein from a different pathway, which aids in cell survival. BAFF stimulation is not only working through the non-canonical NFκB pathway, but is likely involved in crosstalk with the BCR pathway through SYK. This investigation focuses on the mechanism of this crosstalk.
Since NIK is activated in response to BAFF stimulation, it is possible that NIK is also inducing a BCR response through phosphorylation of SYK. The mechanism of this crosstalk is the subject of investigation. CLL cells were cultured on BAFF-expressing (or control) cells under the stromal conditions previously described 17 . Briefly, stromal cells were seeded to achieve 80-100% confluence; on the following day, CLL cells were plated at a 50:1 ratio and incubated at 37 0 C in 5% CO2. 
Methods

Patient samples and cell culture
Cell electroporation
Raji cells (ATCC) were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin. Electroporation of Raji cells was performed using the Amaxa Human B-cell Nucleofection Kit (Lonza, Walkersville, MD). 5x10 6 cells were mixed with 100 µL of Amaxa Solution V, and 2 µg of DNA was nucleofected using program O-017.
Transfection efficiency, assessed by transfection with 2 µg pMaxGFP plasmid, was 70-90% with cell viability of >90% at 24 hours. pCMV4-NIK-HA was a gift from Shao-Cong Sun (Addgene plasmid 27554) 21 . 
Results
BAFF stimulation induces SYK interaction through the NIK/TRAF2/TRAF3 signaling complex
Since we found that BAFF promotes CLL cell survival via SYK-mediated upregulation of the canonical NFκB and Mcl-1, we studied how BAFF activates SYK. BAFF-R signals through an intermediary complex, which involves adaptor proteins TRAF2/TRAF3, NFκB-inducing kinase (NIK), and inhibitor of apoptosis (IAP) family proteins cIAP1/2 13 . While the exact mechanism remains elusive, it is believed that in unstimulated B-cells NIK is constitutively bound to TRAF3
and degraded. When BAFF-R is engaged, the NIK/TRAF/cIAP complex is recruited to the receptor, followed by TRAF3 repression, thus allowing NIK to persist and activate IKK1. IKK1
catalyzes proteasome-assisted processing of NFκB2 (p100) precursor, thereby inducing the noncanonical NFκB 13 . Since targeting NEDD8 with pevonedistat, which blocks p100 processing 17 ,
did not regulate Mcl-1 in BAFF-stimulated CLL cells, we supposed that NIK and/or IKK1 may be responsible for BAFF-induced SYK activation. To study this, we evaluated whether SYK complexes with NIK/TRAF2/TRAF3 in Raji B-cell lymphoma cell line. Immunoprecipitation of cells with SYK monoclonal antibodies showed association of SYK with TRAF3 and TRAF2 in BAFF-stimulated Raji cells (Fig. 1A) . Moreover, we were able to detect NIK in our SYK
immunoprecipitates. Conversely, TRAF2 co-immunoprecipitated with both SYK and NIK in Raji cells, while SYK complexed with TRAF2 and TRAF3 in primary CLL cells ( Fig. 2A-C) .
We subsequently confirmed SYK binding in the reverse experiments with NIK monoclonal antibodies (Fig. 1B) . By contrast, SYK did not complex with IKK1 in either Raji or CLL cells (Fig. 1A and Fig. 2B-C) , strongly suggesting that SYK interacts with submembrane TRAFs in neoplastic B-cells.
As in CLL, BAFF stimulation induced SYK phosphorylation in Raji cells. However, engineered expression of NIK failed to enhance SYK activation either in the absence or in the presence of BAFF (Fig. 2D) . A possible explanation for this is the critical requirement for TRAF2/3 scaffold in NIK-SYK interaction: NIK depletion by means of a genetic knockdown did result in reduced SYK activation (Fig. 1C) . Meanwhile, pharmacologic targeting of IKKs failed to prevent BAFFmediated SYK activation (Fig. 2E) .
Thus, BAFF-BCR crosstalk in neoplastic B-cells is at least in part mediated by SYK interaction with NIK/TRAF2/TRAF3 complex (Fig. 3 ).
Discussion
Along with the BCR, many concurrently active pathways ensure survival of the neoplastic Bcells in the protective niche. Others have previously demonstrated that primary CLL cells cocultured with CD40L-expressing stroma activate the canonical and non-canonical NFκB pathways, accompanied by upregulation of the pro-survival Bcl-2 family proteins (Bcl-xL), and acquire therapeutic resistance, including to BCRi's 15, 16, 17 . BAFF was previously shown to coopt BCR signaling in mouse splenic B-lymphocytes, manifested by phosphorylation of the BCRassociated CD79A subunit and SYK 28 . Here we propose a possible mechanism that facilitates this cross-talk in primary human neoplastic B-cells (Fig. 3) .
We observed direct interaction between NIK/TRAF2/TRAF3 complex and SYK in CLL cells, potentially implicating those two kinases in BAFF-BCR cross-talk in neoplastic B-cells (Fig. 3) .
However, we have not investigated the role of the BCR structures (CD79A/B) or LYN, a BCRassociated kinase constitutively active in CLL cells 29 Thus, this study illuminates the cross-talk between BAFF and BCR signaling pathways in neoplastic B-cells and provides insights into the mechanism of the interaction.
